DK1334983T3 - Inhiberende monoklonalt antistof med proeasen, som aktiverer blodkoaguleringsfaktor VII - Google Patents
Inhiberende monoklonalt antistof med proeasen, som aktiverer blodkoaguleringsfaktor VIIInfo
- Publication number
- DK1334983T3 DK1334983T3 DK03000857T DK03000857T DK1334983T3 DK 1334983 T3 DK1334983 T3 DK 1334983T3 DK 03000857 T DK03000857 T DK 03000857T DK 03000857 T DK03000857 T DK 03000857T DK 1334983 T3 DK1334983 T3 DK 1334983T3
- Authority
- DK
- Denmark
- Prior art keywords
- mab
- fsap
- blood coagulation
- factor vii
- coagulation factor
- Prior art date
Links
- 108010023321 Factor VII Proteins 0.000 title abstract 4
- 230000002401 inhibitory effect Effects 0.000 title 1
- 101001035951 Homo sapiens Hyaluronan-binding protein 2 Proteins 0.000 abstract 8
- 102100039238 Hyaluronan-binding protein 2 Human genes 0.000 abstract 8
- 108010062466 Enzyme Precursors Proteins 0.000 abstract 3
- 102000010911 Enzyme Precursors Human genes 0.000 abstract 3
- 210000004408 hybridoma Anatomy 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108010014172 Factor V Proteins 0.000 abstract 1
- 108010054218 Factor VIII Proteins 0.000 abstract 1
- 102000001690 Factor VIII Human genes 0.000 abstract 1
- 108010049003 Fibrinogen Proteins 0.000 abstract 1
- 102000008946 Fibrinogen Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000003024 amidolytic effect Effects 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229960000301 factor viii Drugs 0.000 abstract 1
- 229940012952 fibrinogen Drugs 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 239000007858 starting material Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96447—Factor VII (3.4.21.21)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10205520A DE10205520A1 (de) | 2002-02-08 | 2002-02-08 | Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1334983T3 true DK1334983T3 (da) | 2006-06-26 |
Family
ID=27588518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03000857T DK1334983T3 (da) | 2002-02-08 | 2003-01-15 | Inhiberende monoklonalt antistof med proeasen, som aktiverer blodkoaguleringsfaktor VII |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7829095B2 (enExample) |
| EP (1) | EP1334983B1 (enExample) |
| JP (1) | JP4398648B2 (enExample) |
| KR (1) | KR100972943B1 (enExample) |
| AT (1) | ATE323107T1 (enExample) |
| AU (1) | AU2003200420B2 (enExample) |
| CA (1) | CA2418411C (enExample) |
| DE (2) | DE10205520A1 (enExample) |
| DK (1) | DK1334983T3 (enExample) |
| ES (1) | ES2259114T3 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19903693A1 (de) * | 1998-04-24 | 1999-10-28 | Centeon Pharma Gmbh | Protease zur Aktivierung des Gerinnungsfaktors VII |
| DE10023923A1 (de) * | 1999-06-10 | 2000-12-14 | Aventis Behring Gmbh | Verfahren zur Bestimmung der Aktivität der Faktor VII-aktivierenden Protease aus Proteinlösungen |
| US7153679B2 (en) * | 2000-07-26 | 2006-12-26 | Aventis Behring Gmbh | Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis |
| EP1650305B1 (de) * | 2000-07-26 | 2009-08-12 | CSL Behring GmbH | Mutanten der den Faktor VII aktivierenden Protease und Nachweisverfahren mit spezifischen Antikörpern |
| DE502006005169D1 (de) * | 2005-12-22 | 2009-12-03 | Siemens Healthcare Diagnostics | Diagnostisches Verfahren zur Erkennung von Trägern der Marburg l-Variante der Faktor VII-aktivierenden Protease (FSAP) anhand differenzieller Modulation der FSAP-Aktivität |
| EP2395354A1 (de) | 2010-06-10 | 2011-12-14 | Siemens Healthcare Diagnostics Products GmbH | Homogener Aktivitätstest zur Bestimmung von enzymatischen Reaktionen |
| CN108409863B (zh) * | 2017-02-10 | 2023-09-26 | 上海仁会生物制药股份有限公司 | 抗凝血因子xi抗体 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US124622A (en) * | 1872-03-12 | Improvement in canal-boats | ||
| US5175087A (en) * | 1987-07-06 | 1992-12-29 | Biopool International, Inc. | Method of performing tissue plasminogen activator assay |
| GB9200417D0 (en) * | 1992-01-09 | 1992-02-26 | Bagshawe Kenneth D | Cytotoxic drug therapy |
| DE19538716A1 (de) * | 1995-10-18 | 1997-04-24 | Behringwerke Ag | Verfahren zur Quantifizierung von aktiviertem Gerinnungsfaktor VII (FVIIa) |
| DE19903693A1 (de) * | 1998-04-24 | 1999-10-28 | Centeon Pharma Gmbh | Protease zur Aktivierung des Gerinnungsfaktors VII |
| DE19937219A1 (de) | 1999-08-06 | 2001-02-08 | Aventis Behring Gmbh | Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie |
| DE10023923A1 (de) * | 1999-06-10 | 2000-12-14 | Aventis Behring Gmbh | Verfahren zur Bestimmung der Aktivität der Faktor VII-aktivierenden Protease aus Proteinlösungen |
| DE19937218A1 (de) | 1999-08-06 | 2001-02-08 | Aventis Behring Gmbh | Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie |
| CA2405550A1 (en) * | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1650305B1 (de) * | 2000-07-26 | 2009-08-12 | CSL Behring GmbH | Mutanten der den Faktor VII aktivierenden Protease und Nachweisverfahren mit spezifischen Antikörpern |
| DE10052319A1 (de) | 2000-10-10 | 2002-04-11 | Aventis Behring Gmbh | Mutante der den Faktor VII aktivierenden Protease |
| DE10036641A1 (de) | 2000-07-26 | 2002-02-14 | Aventis Behring Gmbh | Monoklonale Antikörper für die den Blutgerinnungsfaktor VII aktivierende Protease (FSAP)und ihre Verwendung |
| DE50114021D1 (de) * | 2001-01-08 | 2008-07-24 | Csl Behring Gmbh | Stabilisierte Flüssigzubereitung der den Blutgerinnungsfaktor VII aktivierenden Protease oder ihres Proenzyms |
| DE10148037A1 (de) * | 2001-09-28 | 2003-04-17 | Aventis Behring Gmbh | Verwendung der den Blutgerinnungsfaktor VII aktivierenden Protease zur Prophylaxe und Therapie von vaso-proliferativen Erkrankungen |
| US7454400B2 (en) | 2002-10-24 | 2008-11-18 | Xerox Corporation | System for negotiation with mirroring |
-
2002
- 2002-02-08 DE DE10205520A patent/DE10205520A1/de not_active Withdrawn
-
2003
- 2003-01-15 ES ES03000857T patent/ES2259114T3/es not_active Expired - Lifetime
- 2003-01-15 AT AT03000857T patent/ATE323107T1/de active
- 2003-01-15 DE DE50302926T patent/DE50302926D1/de not_active Expired - Lifetime
- 2003-01-15 DK DK03000857T patent/DK1334983T3/da active
- 2003-01-15 EP EP03000857A patent/EP1334983B1/de not_active Expired - Lifetime
- 2003-02-03 CA CA2418411A patent/CA2418411C/en not_active Expired - Fee Related
- 2003-02-07 JP JP2003030238A patent/JP4398648B2/ja not_active Expired - Fee Related
- 2003-02-07 AU AU2003200420A patent/AU2003200420B2/en not_active Ceased
- 2003-02-07 US US10/359,704 patent/US7829095B2/en not_active Expired - Fee Related
- 2003-02-07 KR KR1020030007874A patent/KR100972943B1/ko not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003200420B2 (en) | 2010-01-28 |
| KR20030067588A (ko) | 2003-08-14 |
| US7829095B2 (en) | 2010-11-09 |
| AU2003200420A1 (en) | 2003-08-28 |
| DE50302926D1 (de) | 2006-05-24 |
| EP1334983A2 (de) | 2003-08-13 |
| EP1334983B1 (de) | 2006-04-12 |
| ATE323107T1 (de) | 2006-04-15 |
| JP2003286300A (ja) | 2003-10-10 |
| US20030215447A1 (en) | 2003-11-20 |
| ES2259114T3 (es) | 2006-09-16 |
| CA2418411C (en) | 2012-10-23 |
| JP4398648B2 (ja) | 2010-01-13 |
| KR100972943B1 (ko) | 2010-07-30 |
| DE10205520A1 (de) | 2003-08-14 |
| CA2418411A1 (en) | 2003-08-08 |
| EP1334983A3 (de) | 2003-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Solberg et al. | A cleaved form of the receptor for urokinase‐type plasminogen activator in invasive transplanted human and murine tumors | |
| CN109154611B (zh) | 人源化抗cd73抗体 | |
| AU2010292342B2 (en) | High affinity human antibodies to human protease-activated receptor-2 | |
| Höyhtyä et al. | Modulation of type‐IV collagenase activity and invasive behavior of metastatic human melanoma (A2058) cells in vitro by monoclonal antibodies to type‐IV collagenase | |
| Kummer et al. | Production and characterization of monoclonal antibodies raised against recombinant human granzymes A and B and showing cross reactions with the natural proteins | |
| WO2008073312B1 (en) | Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof | |
| Nielsen et al. | Urokinase receptor‐associated protein (uPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells | |
| RU2756012C2 (ru) | Антитело против PCSK9 и его применение | |
| DK1334983T3 (da) | Inhiberende monoklonalt antistof med proeasen, som aktiverer blodkoaguleringsfaktor VII | |
| Nuijens et al. | Inactivation of C-1 inhibitor by proteases: demonstration by a monoclonal antibody of a neodeterminant on inactivated, non-complexed C-1 inhibitor | |
| CN101946003A (zh) | 抗adam-15抗体及其应用 | |
| WO2006055704A3 (en) | Antibodies directed to ten-m proteins and uses thereof | |
| CA2911933A1 (en) | Pappalysin regulator | |
| KR20140043795A (ko) | 가용성 인테그린 α4 변이체 | |
| CA2447313A1 (en) | Monoclonal antibody neutralising cathepsin b activity and uses thereof | |
| ATE370163T1 (de) | Antikörper zur isolierung und/oder identifizierung mesenchymaler stammzellen und verfahren zur isolierung und/oder identifizierung mesenchymaler stammzellen | |
| US6025142A (en) | Hydrophobic u-PAR binding site | |
| US20230220112A1 (en) | Antibodies for binding plasmin | |
| EP1856155B1 (en) | Monoclonal antibodies and immunodetection assay specific for the chemotactic epitope of the urokinase-type plasminogen activator receptor | |
| Faber-Elmann et al. | A peptide based on an anti-DNA autoantibody downregulates matrix metalloproteinases in murine models of lupus | |
| Sgier et al. | Isolation and characterization of an inhibitory human monoclonal antibody specific to the urokinase-type plasminogen activator, uPA | |
| AU2006235695B2 (en) | Cathepsin S antibody | |
| Harada et al. | Identification of epitopes recognized by a panel of six anti-human IgG2 monoclonal antibodies | |
| KR20110093298A (ko) | 유비퀴틴 특이적 프로세싱 프로테아제 17에 특이적으로 결합하는 항체 | |
| JP2002065266A (ja) | 気道特異的トリプシン様酵素およびその利用法 |